Andriy Yagensky

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 227 citations · Full text

Medicine, Cardiology, Pharmacology +14

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of blood pressure and lipid lowering on cognition

Jackie Bosch, Martin O’Donnell, Balakumar Swaminathan et al. · Neurology · 2019 · 82 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Preliminary Evidence for the Cross-Cultural Utility of the Type D Personality Construct in the Ukraine

Susanne S. Pedersen, Andriy Yagensky, Otto R.F. Smith et al. · International Journal of Behavioral Medicine · 2009 · 57 citations · Full text

Social Sciences, Behavioral Sciences, Psychology +16